Joseph Chiesa

1.9k total citations · 1 hit paper
9 papers, 748 citations indexed

About

Joseph Chiesa is a scholar working on Molecular Biology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Joseph Chiesa has authored 9 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Surgery and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Joseph Chiesa's work include Lipoproteins and Cardiovascular Health (3 papers), Amino Acid Enzymes and Metabolism (1 paper) and Chemical Synthesis and Analysis (1 paper). Joseph Chiesa is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Amino Acid Enzymes and Metabolism (1 paper) and Chemical Synthesis and Analysis (1 paper). Joseph Chiesa collaborates with scholars based in United Kingdom, United States and Sweden. Joseph Chiesa's co-authors include Verena Karsten, Akshay Vaishnaw, Saraswathy V. Nochur, Jared Gollob, Brian R. Bettencourt, Renta Hutabarat, Jeffrey Cehelsky, Amy Simon, Timothy Mant and Kevin Fitzgerald and has published in prestigious journals such as The Lancet, Circulation and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Joseph Chiesa

9 papers receiving 725 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

2013 467 citations Kevin Fitzgerald, Maria Frank-Kamenetsky et al. The Lancet profile →

Peers

Joseph Chiesa

MB

SURGE

CR

IMMUN

CCM

Angela Raymond Canada

Francine Sirois Canada

John Blakemore United States

Robert Dullea United States

Alexandra C. Chadwick United States

Laura Nasarre Spain

Ali Al‐Hashimi Canada

Steven V. Molinski Canada

Susan M. Meyn United States

Angela Raymond Canada

Joseph Chiesa

286 ×0.7

MB

563 ×2.1

SURGE

114 ×0.8

CR

95 ×1.2

IMMUN

64 ×0.9

CCM

Citations per year, relative to Joseph Chiesa Joseph Chiesa (= 1×) peers Angela Raymond

Countries citing papers authored by Joseph Chiesa

Since Specialization

Citations

This map shows the geographic impact of Joseph Chiesa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Chiesa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Chiesa more than expected).

Fields of papers citing papers by Joseph Chiesa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Chiesa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Chiesa. The network helps show where Joseph Chiesa may publish in the future.

Co-authorship network of co-authors of Joseph Chiesa

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Chiesa. A scholar is included among the top collaborators of Joseph Chiesa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Chiesa. Joseph Chiesa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Zimmermann, Tracy, Verena Karsten, Amy Chan, et al.. (2017). Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Molecular Therapy. 25(1). 71–78. 157 indexed citations

2.

Taubert, Max, et al.. (2017). Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 61(10). 2 indexed citations

3.

Lues, Inge, Frank Weber, Antje Meyer, et al.. (2015). A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimer s & Dementia Translational Research & Clinical Interventions. 1(3). 182–195. 46 indexed citations

4.

Westerberg, Göran, Joseph Chiesa, Claus A. Andersen, et al.. (2014). Safety, pharmacokinetics, pharmacogenomics and QT concentration−effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. British Journal of Clinical Pharmacology. 79(3). 477–491. 46 indexed citations

5.

Qin, Yan, et al.. (2014). Abstract 11889: Phase Ib Study of Icosabutate, a Novel Structurally Enhanced Fatty Acid, in Subjects With Hypercholesterolemia. Circulation. 130(suppl_2). 6 indexed citations

6.

Fitzgerald, Kevin, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, et al.. (2013). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet. 383(9911). 60–68. 467 indexed citations breakdown →

7.

Zimmermann, Tracy, Verena Karsten, Jamie Harrop, et al.. (2013). Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC). Journal of Cardiac Failure. 19(8). S66–S66. 15 indexed citations

8.

Zhang, Wei, et al.. (2012). QT effect of semagacestat at therapeutic and supratherapeutic doses. International Journal of Clinical Pharmacology and Therapeutics. 50(4). 290–299. 2 indexed citations

9.

Fitzgerald, Kevin, Maria Frank-Kamenetsky, Timothy Mant, et al.. (2012). Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology. 32(suppl_1). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact